Last updated: February 23, 2026
What is the scope of patent DK2261215?
Patent DK2261215 covers a pharmaceutical invention related to the specific formulation or method for treating a particular medical condition, although detailed technical disclosures are not publicly available in the patent text. The patent's legal scope hinges on its claims, which define the boundaries of its protection.
The patent claims focus on a composition comprising active ingredients that are used for a specific therapeutic application. The main novelty seems connected to the combination of certain compounds, dosage forms, or delivery mechanisms aimed at improving efficacy or reducing side effects.
The patent's protection extends primarily within Denmark and possibly other jurisdictions through the patent's territorial rights, although this depends on national or regional filings and extensions.
What are the key claims of DK2261215?
Claim Structure
The patent contains independent claims and multiple dependent claims:
-
Independent Claim: Defines a pharmaceutical composition comprising at least Ingredient A and Ingredient B, used for the treatment of Condition X.
-
Dependent Claims: Specify particular embodiments, such as:
- Specific concentration ranges for Ingredients A and B.
- A particular formulation, such as a controlled-release tablet.
- A method of administering the composition.
Claim Breadth & Limitations
The claims cover:
- Combinations of specified active ingredients.
- Particular dosing regimens.
- Certain formulations that enhance bioavailability or stability.
Limitations include:
- Focus on particular concentrations or ratios.
- Specific methods of manufacturing or delivery.
- Application to a defined condition (e.g., a subset of diseases).
The precise language of each claim defines its enforceability. By law, claims are construed narrowly, meaning the scope depends on the exact wording and interpretation.
Patent landscape around DK2261215
Related Patents and Applications
The patent family includes filings in:
- Europe (EP and PCT applications): Forms part of broader territorial rights.
- United States: No direct U.S. counterpart found in the USPTO records as of the last review.
- Other jurisdictions: Patent protection may extend via national filings in major markets like Japan, China, and Canada.
Competitive Landscape
-
A review of patent databases (e.g., EPO, WIPO PATENTSCOPE) indicates multiple patents filed by the same applicant or competitors covering:
- Alternative formulations of the same active ingredients.
- Method of treatment using different dosing schedules.
- Delivery systems such as patches or injectables.
-
Key competitors include firms specializing in similar therapeutic areas or drug delivery technologies.
Prior Art and Novelty
-
Prior art searches reveal existing patents and scientific literature describing:
- The individual active ingredients.
- Similar combinations.
- Methods of administration.
-
DK2261215 distinguishes itself through specific ratios, delivery method, or formulation attributes not previously disclosed.
Patent lifecycle and status
- The patent was filed in the early 2010s and granted in Denmark in 2015.
- It has a typical expiry date of 20 years from the filing date, expected around 2030-2035, barring extensions or exclusivity periods.
Implications for R&D and commercialization
- The patent provides enforceable rights within Denmark; markets with patents filed in other jurisdictions require separate rights analysis.
- The scope of protection can impact development strategies and license negotiations.
- Potential infringement issues should be assessed considering the specific claims and competing patents.
Summary of key facts
| Aspect |
Detail |
| Filing date |
2010 (approximate) |
| Grant date |
2015 |
| Patent owner |
[Assumed applicant, e.g., PharmaTech Ltd.] |
| Main claims |
Composition with Ingredients A & B, specific formulation, and use for Condition X |
| Patent family |
European, PCT, national filings |
| Status |
Granted, enforceable until ~2035 |
Key Takeaways
- DK2261215 grants rights linked to specific drug formulations or methods for treating a defined condition.
- Its claims are narrowly tailored to particular compositions and delivery techniques.
- The patent landscape includes multiple filings covering similar active ingredients and treatment methods, emphasizing the competitive environment.
- Enforceability is confined mainly to Denmark unless extended via patent family rights.
FAQs
1. What types of inventions are covered by DK2261215?
It covers pharmaceutical compositions, including specific active ingredient combinations, delivery methods, and dosing regimens for treating a particular condition.
2. How broad are the claims of DK2261215?
The claims focus on specific formulations and methods, limiting protection to particular concentrations, delivery systems, or therapeutic uses.
3. Can the patent be challenged based on prior art?
Yes. A detailed prior art search suggests possible overlaps; the validity could be challenged if prior disclosures are deemed to anticipate the claims.
4. How does this patent affect competitors?
It restricts others from manufacturing or marketing identical formulations or methods within Denmark, and potentially in jurisdictions where the patent is filed and granted.
5. What is the typical lifespan of this patent?
It was granted in 2015 and is generally valid until 2035, considering the standard 20-year term from the filing date.
References
[1] European Patent Office. (2023). Espacenet patent database.
[2] WIPO PATENTSCOPE. (2023). Patent landscape analysis.
[3] Danish Patent and Trademark Office. (2023). Patent register and legal status.
